Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABBV | AbbVie Inc.

IndexS&P 500 P/E31.42 EPS (ttm)4.86 Insider Own0.13% Shs Outstand1.77B Perf Week0.41%
Market Cap272.29B Forward P/E13.81 EPS next Y11.06 Insider Trans-4.52% Shs Float1.76B Perf Month3.85%
Income8.63B PEG- EPS next Q2.87 Inst Own70.90% Short Float / Ratio0.71% / 2.51 Perf Quarter12.37%
Sales56.02B P/S4.86 EPS this Y2.70% Inst Trans0.10% Short Interest12.45M Perf Half Y-1.65%
Book/sh7.28 P/B20.98 EPS next Y0.03% ROA6.30% Target Price169.42 Perf Year8.86%
Cash/sh4.92 P/C31.06 EPS next 5Y-4.13% ROE58.20% 52W Range130.96 - 168.11 Perf YTD-5.49%
Dividend5.92 P/FCF10.98 EPS past 5Y13.30% ROI20.50% 52W High-9.14% Beta0.53
Dividend %3.88% Quick Ratio0.80 Sales past 5Y15.50% Gross Margin70.50% 52W Low16.63% ATR2.25
Employees50000 Current Ratio0.90 Sales Q/Q-4.90% Oper. Margin31.00% RSI (14)60.31 Volatility1.31% 1.41%
OptionableYes Debt/Eq4.74 EPS Q/Q121.10% Profit Margin15.40% Rel Volume0.61 Prev Close153.43
ShortableYes LT Debt/Eq4.34 EarningsJul 27 BMO Payout118.50% Avg Volume4.97M Price152.74
Recom2.40 SMA202.13% SMA503.45% SMA2001.81% Volume3,048,684 Change-0.45%
Date Action Analyst Rating Change Price Target Change
Jul-25-23Initiated William Blair Mkt Perform
Jul-14-23Initiated HSBC Securities Buy $167
Apr-05-23Downgrade Argus Buy → Hold
Mar-01-23Initiated Guggenheim Buy $172
Feb-22-23Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23Upgrade SVB Securities Underperform → Market Perform $135 → $153
Nov-18-22Initiated Credit Suisse Outperform $170
Nov-08-22Downgrade Societe Generale Buy → Hold
Aug-01-22Downgrade Atlantic Equities Overweight → Neutral $178 → $162
May-23-22Initiated SVB Leerink Underperform $140
Sep-22-23 05:03PM
04:28PM
03:47PM
Sep-21-23 04:06PM
01:54PM
10:15AM Loading…
10:15AM
Sep-19-23 04:18PM
Sep-18-23 05:45PM
09:00AM
09:00AM
Sep-15-23 09:33AM
09:15AM
08:32AM
Sep-14-23 05:00AM
Sep-13-23 08:12PM
11:00AM Loading…
11:00AM
10:02AM
09:30AM
Sep-12-23 05:16PM
05:11PM
09:30AM
08:30AM
Sep-11-23 05:45PM
03:30PM
09:12AM
Sep-08-23 12:10PM
11:23AM
Sep-07-23 07:00AM
Sep-06-23 11:14AM
08:45AM
08:00AM Loading…
08:00AM
07:03AM
01:36AM
Sep-05-23 05:45PM
09:51AM
09:00AM
Sep-02-23 07:35AM
06:55AM
Sep-01-23 09:39AM
Aug-31-23 11:10PM
11:22AM
Aug-30-23 02:26PM
01:25PM
01:25PM
11:33AM
09:00AM
Aug-29-23 05:12PM
04:07PM
02:45PM
12:25PM
10:47AM
09:45AM
09:28AM
09:21AM
Aug-28-23 08:45AM
Aug-27-23 09:47AM
Aug-26-23 06:55AM
Aug-25-23 09:59AM
09:21AM
09:00AM
Aug-24-23 12:50PM
11:03AM
10:53AM
10:42AM
Aug-23-23 04:51PM
04:22PM
Aug-22-23 03:50PM
Aug-21-23 07:24PM
12:58PM
Aug-18-23 11:38AM
Aug-17-23 08:31PM
11:43AM
08:45AM
02:00AM
Aug-15-23 05:15PM
07:58AM
07:00AM
Aug-14-23 04:03PM
08:01AM
05:50AM
Aug-12-23 06:15AM
Aug-10-23 10:00AM
Aug-09-23 10:23AM
09:24AM
Aug-08-23 05:37AM
Aug-06-23 07:01AM
Aug-04-23 12:12PM
11:36AM
08:19AM
07:28AM
Aug-03-23 09:45AM
07:15AM
07:00AM
Aug-02-23 01:40PM
11:49AM
Aug-01-23 04:45PM
01:30PM
08:45AM
05:50AM
Jul-31-23 11:09AM
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behcet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD ACHAIRMAN OF THE BOARD AND CEOAug 01Sale148.5860,0008,914,800565,294Aug 02 05:07 PM
GONZALEZ RICHARD ACHAIRMAN OF THE BOARD AND CEOJul 31Sale149.1518,5002,759,275625,294Aug 02 05:07 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 25Option Exercise144.546,130886,03041,460Apr 27 05:00 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 25Sale165.006,1301,011,45035,330Apr 27 05:00 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 17Sale161.677,4991,212,33835,330Apr 19 05:00 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 03Option Exercise93.5015,0021,402,68757,831Apr 05 05:00 PM
Siatis Perry CEVP, GC AND SECRETARYApr 03Option Exercise105.923,520372,83813,897Apr 05 05:00 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 03Sale160.0315,0022,400,77042,829Apr 05 05:00 PM
Siatis Perry CEVP, GC AND SECRETARYApr 03Sale160.003,520563,20010,377Apr 05 05:00 PM
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERMar 13Option Exercise54.8621,8101,196,497114,066Mar 15 05:00 PM
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERMar 13Sale152.2853,1258,089,99860,941Mar 15 05:00 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSMar 01Option Exercise93.5015,0031,402,78057,832Mar 02 05:07 PM
SALEKI-GERHARDT AZITAEVP, OPERATIONSMar 01Option Exercise51.4226,9901,387,826226,839Mar 02 05:01 PM
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICERMar 01Sale153.2844,1416,766,10313,837Mar 02 04:30 PM
SALEKI-GERHARDT AZITAEVP, OPERATIONSMar 01Sale154.4836,9905,714,215189,849Mar 02 05:01 PM
Reents Scott TEVP, CHIEF FINANCIAL OFFICERMar 01Sale153.0815,9422,440,355809Mar 02 05:04 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSMar 01Sale155.0015,0032,325,46542,829Mar 02 05:07 PM
Siatis Perry CEVP, GC AND SECRETARYMar 01Sale153.0812,1351,857,64110,377Mar 02 05:06 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSFeb 21Option Exercise105.9215,3211,622,80078,000Feb 21 06:12 PM
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTHFeb 21Option Exercise61.5714,179872,94966,462Feb 21 06:14 PM
Siatis Perry CEVP, GC AND SECRETARYFeb 21Option Exercise93.507,364688,53439,532Feb 22 05:00 PM
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTHFeb 21Sale151.0428,5414,310,77137,921Feb 21 06:14 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSFeb 21Sale151.0415,3212,314,11962,679Feb 21 06:12 PM
Siatis Perry CEVP, GC AND SECRETARYFeb 21Sale151.037,3641,112,17832,168Feb 22 05:00 PM
SALEKI-GERHARDT AZITAEVP, OPERATIONSFeb 17Option Exercise51.4225,0001,285,500258,208Feb 21 06:13 PM
SALEKI-GERHARDT AZITAEVP, OPERATIONSFeb 17Sale149.5325,0003,738,144233,208Feb 21 06:13 PM
AUSTIN ROXANNE SDirectorFeb 17Sale150.5010,0001,505,00040,705Feb 21 06:16 PM
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICERDec 12Option Exercise54.8642,3702,324,41856,207Dec 14 05:06 PM
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICERDec 12Sale163.4442,3706,925,01813,837Dec 14 05:06 PM